Send SMS
+918037301152

0.5 mg Entekor Entecavir

0.5 mg Entekor Entecavir
0.5 mg Entekor Entecavir
Send Inquiry
Product Code : Ente-13
Brand Name : Aprazer Healthcare
Price And Quantity
  • Minimum Order Quantity
  • 1 Box
  • Price
  • 1200 INR
Product Specifications
  • Grade
  • Pharmaceutical
  • Formulations Type
  • External Use Drugs
  • Formulations Form
  • Tablets
  • Treatments & Functions
  • Chronic Hepatitis B
  • Gender/Age Group
  • Suitable For All Ages, Women, Adult, Children, Infants
  • Dosage Guidelines
  • 0.5 mg
  • Storage Instructions
  • Dry Place
Product Description

 ENTECAVIR 0.5 mg

Each film-coated tablet contains.

Entecavir IP…………………………………………………………….0.5mg

Colour: Titanium Dioxide IP & Red Oxide of Iron

DOSAGE FORM

  • Oral film-coated tablet
  • PHARMACOLOGY
  • Pharmacodynamics

 Mechanism of action

Entecavir is an antiviral drug.Entecavir a guanosine nucleoside analogue with activity against HBV reverse transcriptase (rt).is efficiently phosphorylated to the active triphosphate form which has

an intracellular half-life functionally inhibits all three activities of the HBV reserve transcriptase:

Base priming.(2) reverse transcription of the negative strand from the pregenomic messenger

RNA and (3) synthesis of the positive strand of HBV DNA Entecavir in phosphate is a weak inhibitor

Of cellular DNA polymerases α β and δ and mitochondrial DNA polymerase gamma with K, values

Ranging from 18 to<160 Γm.Antiviral Activity.Entecavir inhibited HBV DNA synthesis(50%

Reduction, EC) at a concentration of 0.004 ΓM in human HepG2 cells transfected with wild-type HBV.The median EC value for entecavir against lamivudine-resistant  HBV (rtl 180M, Tm204v)

Was 0.026 ΓM.(range 0.010 to 0.059 ΓM) The co-administration of HIV nucleoside/ nucleotide

Reverse transcriptase inhibitors (NRTIs) with entecavir is unlikely to reduce the antiviral efficacy

Of entecavir against HBV or of any of these agents against HIV,in HBV combination assays in cell culture,abacavir,didanosine,lamivudine,stavudine,tenofovir or zidovudine were not antagonistic to the cell culture anti-HIV activity of these six NRTIs or emtricitabine at concentrations greater than 100 time C max of entecavir using 1 mg dose.

Antiviral Activity against HIV

Analysis of the inhibitory activity of entecavir against a panel of laboratory and clinical HIV type 1(HIV-1) isolates using a variety of cells  and assay conditions yielded EC50 values ranging from

0.026 to >10 ΓM; the lower EC50 values were observed when decreased levels of virus were

Used in the assay.in cell culture entecavir selected for an M1841 substitution in HIV variants

Containing the M184V substitution showed loss of susceptibility to entecavir.

Pharmacokinetics.

The single- and multiple-dose pharmacokinetics of entecavir were evaluated in healthy subjects And subjects with chronic HBV infection. Absorption.following oral administration in healthy Subjects, entecavir peak plasma concentration occurred between 0.5 and 1.5 hours.following

Multiple daily doses ranging from 0.1to 1.0 mg.CMAX and area under the concentration-time curve (AUC) at steady state increased in proportion to dose.Steady state was achieved after 6 to 10 days of once-daily administration with approximately 2-fold accumulation.for a 0.5 mg oral

Dose, CMAX at steady state was 4.2ng/ML.and trough plasma concentration (C1rough) was 0.3 ng/ML.for a 1mg oral dose. CMAX at steady state was 4.2ng/ML and trough plasma concentration( CMAX ) was 0.3 ng/ml for a 1 mg oral dose CMAX was 8.2ng/ml and C1rough was 0.5ng.ml.Effects of Food on Oral Absorption: Oral administration of 0.5 mg of entecavir with a

Standard high-fat meal (945 kcal,54.6 g fat)or a light meal(379 kcal.8.2 g fat) resulted in a delay

In absorption (1.0-1.5 hours fed versus 0.75 hours fasted).a decrease in AUC of 18-20%[see DOSAGE ANDADMINISTRATION].

Trade Information
  • Payment Terms
  • Letter of Credit (L/C)
  • Supply Ability
  • 100 Box Per Week
  • Delivery Time
  • 2-3 Days
  • Main Export Market(s)
  • Africa, Middle East, Western Europe, Eastern Europe, South America, North America, Central America, Australia, Asia

GANDHI MEDICOS
X


Disclaimer:-

The information on the website www.gandhimedicosindia.com is for your information purposes only and is not a substitute for professional medical advice, diagnosis and treatment. Please consult with your doctor before using any product discussed within this website.
Back to top